The global travel vaccines market size was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 10.0 Billion by 2033, exhibiting a growth rate (CAGR) of 9.36% from 2025 to 2033.
To get more information on this market, Request Sample
The increasing popularity of international travel among people across the globe drives the industry expansion. In 2024, more than 1 billion international tourists were chronicled between January and September. As globalization and travel become more accessible, the risk of infection across the world increases. Travelers are going to places with different illnesses, which is further stimulating the demand for vaccines. This trend is also supported by the surge in leisure travel and international students studying abroad. Furthermore, the desire for exotic and unique travel experiences is driving people to visit areas with distinct health concerns, emphasizing the importance of specific immunizations.
Additionally, the rising government regulations regarding vaccination requirements are propelling the market growth. Also, governments across the globe understand the importance of public health during international travel, which has further surged the demand for these vaccines. The WHO's international health regulations require travelers coming to specific countries to confirm yellow fever vaccination. Furthermore, several governments provide subsidized or free travel vaccines to their residents. In June 2024, Uganda announced that it would require everyone to have yellow fever vaccines, whoever is traveling to and from the country. Also, the authorities of the country have vaccinated more than 12 million people. Furthermore, the residents were offered free-of-cost single-dose vaccines, further propelling the industry’s growth. Besides this, the changing nature of disease patterns is driving the market expansion. Infectious diseases are constantly changing and spreading to new areas, which makes ongoing vaccine research and development essential. Also, diseases like Zika and Ebola have become major concerns for travelers, thereby increasing the need for vaccines.
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America has a dominance in the market share due to the elevating concerns over health and safety.
North America acquires the largest share. The surging concerns among people regarding travel related diseases in the region are stimulating the market growth in the region. Also, the CDC in the United States recommends Mpox vaccination for anyone traveling to countries where clade I Mpox is still being transmitted from person to person, thereby further propelling the industry's growth.
In Europe, the growing focus on research and development of advanced travel vaccines is accelerating the market demand. In addition, various countries, like Germany and the UK, are innovating vaccines for travel-related diseases like dengue. Additionally, the European Medicines Agency (EMA) ensures quality standards, boosting traveler confidence. High outbound tourism rates from Europe to tropical regions also contribute to the growing demand for pre-travel vaccinations.
The growing middle-class population and the increasing international travel in the Asia Pacific region have supported market demand. In addition, the inflating prevalence of several diseases across India is acting as another significant growth-inducing factor. Furthermore, governments in the region are also actively supporting vaccination programs, which is further stimulating the industry’s growth.
The heightened awareness regarding disease prevention in the Middle East and Africa is stimulating the market growth. Saudi Arabia being a popular destination for pilgrimage exposes various infections, further propelling the demand for these vaccines. Also, government initiatives promoting vaccination and stringent travel requirements for disease-prone areas further boost the industry's demand.
The rising efforts to combat endemic diseases across the Latin America region are propelling the market demand. Moreover, countries like Brazil require vaccination proof for travelers going to high-risk areas. Apart from this, the surging outbound travel from countries like Mexico and Argentina to areas that require vaccination is also supporting the demand for these vaccines.
Some of the leading travel vaccines market companies include GlaxoSmithKline Pharmaceuticals Limited, Sanofi Pasteur, Merck & Co., Inc., Novartis AG, Pfizer Inc., ALK-Abelló A/S, Bavarian Nordic A/S, Crucell (Subsidiary of Johnson & Johnson), CSL Limited, AstraZeneca PLC, Altimmune, Inc., Abbott Laboratories, Hoffmann-La Roche, Inc., among many others. Sanofi Pasteur invested in a new vaccine manufacturing facility in Toronto, Canada. The investment in a new facility boosted antigen and filler capacity for Sanofi's high dose quadrivalent influenza vaccine.
Report Features | Details |
---|---|
Market Size in 2024 | USD 4.4 Billion |
Market Forecast in 2033 | USD 10.0 Billion |
Market Growth Rate 2025-2033 | 9.36% |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Compositions Covered | Mono Vaccines, Combination Vaccines |
Diseases Covered | Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | GlaxoSmithKline Pharmaceuticals Limited, Sanofi Pasteur, Merck & Co., Inc., Novartis AG, Pfizer Inc., ALK-Abelló A/S, Bavarian Nordic A/S, Crucell (Subsidiary of Johnson & Johnson), CSL Limited, AstraZeneca PLC, Altimmune, Inc., Abbott Laboratories, Hoffmann-La Roche, Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |